★
CNTA
Centessa Pharmaceuticals PLC · Biotechnology
FCF-$209mF
Rev——
D/E0.21A-
P/S——
PEG——
56Score
$39.781Y Target$53.70Near-term target
5Y Target$80.01Compound horizon
10Y Target$208.20Long-dated conviction
FCF-$209mTTM · 03/26F
FCF is negative (-$209m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev—TTM YoY—
Revenue growth data unavailable or not applicable — neutral default · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.21totalA-
D/E 0.21 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S——
P/S unavailable
PEG—proxy—
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $6.2b. Trading near 52-week high of $40.26 — momentum setup, limited technical margin of safety.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$209m) — capital raises or debt issuance likely required; dilution / leverage risk. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -60% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $53.70 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $80.01 — requires the platform / technology to reach commercial scale. 10 yr $208.20 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CNTA
Shares to buy
50
Position size
$1,989
4.0% of portfolio
Stop price
$29.84
25% below $39.78
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.